long intergenic non-protein coding RNA 2764Genealiases: []
Q-omics provides the consensus-scored LINC02764 profile across patient tissues and cancer cell-line models. LINC02764 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, LINC02764 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, LINC02764 RNA expression shows 6,357 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LGG, HNSC, and STAD as cancer lineages where LINC02764 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02764 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02764 survival associations across molecular data types. LINC02764 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02764 RNA expression–survival associations across cancer types. High LINC02764 expression shows unfavorable associations in ESCA, BRCA and SKCM, but favorable associations in LGG, KIRC and UCS. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for LINC02764 RNA expression.
This table summarizes LINC02764 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02764. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02764 shows lower tumor expression in COAD and higher tumor expression in HNSC, LUSC, KICH and LIHC. The HNSC box plot shows higher LINC02764 RNA expression in tumor versus normal tissue (log2 FC = +0.068, t-test p = .007).
This table shows molecular features associated with LINC02764 in patient tissues and cancer cell lines. In patient samples, LINC02764 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
